Prelude Therapeutics Incorporated Share Price
PRLDPrelude Therapeutics Incorporated Stock Performance
Open $4.36 | Prev. Close $4.38 | Circuit Range N/A |
Day Range $4.08 - $4.36 | Year Range $0.73 - $5.54 | Volume 11,264 |
Average Traded $4.18 |
Prelude Therapeutics Incorporated Share Price Chart
About Prelude Therapeutics Incorporated
Prelude Therapeutics Incorporated, a clinical-stage precision oncology company, focuses on the discovery and development of novel precision cancer medicines to underserved patients. It is developing PRT3789, a selective degrader of SMARCA2 protein for the treatment of advanced or metastatic solid tumors with loss of SMARCA4 due to truncating mutation and/or deletion; PRT7732, a selective and orally bioavailable SMARCA2 degraders to treat advanced or metastatic solid tumors; and PRT2527, a cyclin-dependent kinase 9 inhibitor for the treatment of advanced solid tumors. The company's CDK9 program is a regulator of cancer-promoting transcriptional programs, including MCL1, MYC, and MYB. Prelude Therapeutics Incorporated was incorporated in 2016 and is based in Wilmington, Delaware.
Prelude Therapeutics Incorporated Historical Data
| Day | Open | Close | Change % |
|---|---|---|---|
29-Apr-26 | $4.36 | $4.25 | +0.00% |
29-Apr-26 | $4.36 | $4.25 | -5.65% |
27-Apr-26 | $4.97 | $4.51 | -3.94% |
24-Apr-26 | $4.49 | $4.70 | +8.55% |
23-Apr-26 | $4.35 | $4.33 | +0.12% |
22-Apr-26 | $4.72 | $4.32 | -7.00% |
21-Apr-26 | $4.70 | $4.64 | +3.22% |